Resources Repository
-
BookPublication 2016Cost-Effectiveness Analysis in Health: A Practical Approach, 3rd Edition
Cost-Effectiveness Analysis in Health provides an introduction to the tools, methods, and procedures used to perform cost-effectiveness research. …
Cost-Effectiveness Analysis in Health provides an introduction to the tools, methods, and procedures used to perform cost-effectiveness research. This third edition contains new discussion on meta-analysis and advanced modeling techniques, a worked example using visual modeling software TreeAge Pro, and updated recommendations from the U.S. Public Health Service's Panel on Cost-Effectiveness in Health and Medicine. The book provides process-specific instruction in a concise, structured format to highlight common methods and techniques for: 1) Developing a thoroughly fleshed-out research project; 2) Working…
Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Preferences/Values | Evidence Synthesis | Technology Assessment | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | North America -
ArticlePublication 2015Broader Economic Impact of Vaccination: Reviewing and Appraising the Strength of Evidence
Economic evaluations of public health programs such as immunization often consider only direct health benefits and …
Economic evaluations of public health programs such as immunization often consider only direct health benefits and medical cost savings. Evidence linking immunization to important benefits in indicators such as childhood development, household behavior, and other macro-economic data are unclear. A conceptual framework of the pathways between immunization and these broader economic benefits was developed through expert consultation. The authors obtained articles from previous reviews, snowballing, and expert consultation, and associated them with one of the pathways and assessed them using modified Grading…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Costing Methods | Preferences/Values | Priority Setting/Ethics | Evidence Synthesis | Infectious Diseases | Social Determinants | Economics/Finance | Education/Labor | Health/Medicine -
ArticlePublication 2015Achieving a 'Grand Convergence' in Global Health
The Commission on Investing in Health published its report, GlobalHealth2035, in 2013, estimating an investment …
The Commission on Investing in Health published its report, GlobalHealth2035, in 2013, estimating an investment case for a grand convergence in health outcomes globally. In support of the drafting of the Sustainable Development Goals (SDGs), this paper presents estimates of what the grand convergence investment case might achieve—and what investment would be required—by 2030. The authors start with a country-based (bottom-up) analysis of the costs and impact of…!--?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /-->
Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Health Systems | Global Governance | Economics/Finance | Health/Medicine | Science/Technology | Global -
ReviewPublication 2015Major Concepts of Health Care Economics
This article provides a short simple guide to major economic concepts, such as supply, demand, monopoly, …
This article provides a short simple guide to major economic concepts, such as supply, demand, monopoly, monopsony, adverse selection, and moral hazard. Concepts are applied to central features of U.S. health care to illuminate some of the principal problems of health policy - high cost and the uninsured - and explain why solutions are difficult to obtain.
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Costing Methods | Health/Medicine | North America -
ArticlePublication 2015Universal Public Finance of Tuberculosis Treatment in India: An Extended CEA
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India …
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India using extended cost-effectiveness analysis (ECEA). The authors evaluated the impact of UPF on health gains, financial consequences, and catastrophic health expenditures, and concluded that the health gains and insurance value of UPF would accrue mostly to the poor. However, reductions in out-of-pocket expenditures were found to be more uniformly distributed across income quintiles. A variant on the base case suggests…
Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Priority Setting/Ethics | Infectious Diseases | Social Determinants | Health Systems | Policy/Regulation | Clinical Care | Economics/Finance | Health/Medicine | Asia & Pacific -
ArticlePublication 2015Extended Cost-Effectiveness Analysis of Treatment and Prevention of Diarrhoea in Ethiopia
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits …
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits due to the treatment and prevention of diarrhoea (i.e., rotavirus vaccination) in Ethiopia. The authors use an economic model to examine the impacts of universal public finance (UPF) of diarrhoeal treatment alone, as opposed to diarrhoeal treatment along with rotavirus vaccination using extended cost-effectiveness analysis (ECEA). The study finds that diarrhoeal treatment paired with rotavirus vaccination is more cost effective…
Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Priority Setting/Ethics | Infectious Diseases | Child/Nutrition | Social Determinants | Environmental Health | Health Systems | Climate/Environment | Economics/Finance | Health/Medicine | Sub-Saharan Africa -
ReportPublication 2015Modeling to Improve Policy Decisions in the Americas: Noncommunicable Diseases
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only …
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only to human health, but also to a country’s economic development and growth. The evidence on both of these counts is compelling. In 2012, cardiovascular disease, diabetes, cancers, chronic respiratory conditions including asthma, and other NCDs were the cause of 4.5 million deaths in the Americas. Of that total number, 1.5 million of them were premature, occurring among people aged 30-69…
Cost-Effectiveness Analysis | Decision Analysis | Costing Methods | Priority Setting/Ethics | Mathematical Models | State-Transition | Microsimulation | Chronic Disease/Risk | Mental Health | Health/Medicine | Latin America & Caribbean -
GuidelinesPublication 2014Methods for Economic Evaluation Project
This report details the work of the Methods for Economic Evaluation Project (MEEP), which aims …
This report details the work of the Methods for Economic Evaluation Project (MEEP), which aims to promote a consistency in the methods used for economic evaluations. The report is targeted especially at low and middle-income countries (LMICs). The Bill and Melinda Gates Foundation is a major funder of health economic evaluations in LMICs, but there is substantial variation in the methods used and the quality of the analyses produced. The report drew on expertise from…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Costing Methods | Priority Setting/Ethics | Climate/Environment | Education/Labor | Health/Medicine | Global -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Cost-Effectiveness Analysis | Costing Methods | Health Outcomes | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific